Nearly 6% of adults globally will experience depression at some point in their lives. It’s alarming that suicide, often linked to depression, is among the leading causes of death in the U.S. In 2023, over 49,000 Americans died by suicide following about 1.5 million attempts, according to CDC data.
For years, mental health experts noted a connection between poor diet and severe depression. Diets high in processed meats and unhealthy fats can worsen mental health. Despite this knowledge, new drug treatments haven’t emerged. However, a promising discovery from Kyoto University might change that.
Researchers led by Kousaku Ohinata have identified a novel peptide that may interact with the gut-brain axis. This peptide targets receptors in the gut and modulates the vagus nerve, a crucial pathway for neurocommunication. During a presentation at TIDES Asia 2026, Ohinata emphasized that this discovery highlights the gut’s importance in mental health and could offer new treatments for those battling depression.
Ohinata’s team is collaborating with Viage Therapeutics to explore these peptide-based treatments. “We eat many different food molecules every day,” he explained. These peptides can impact mental health, showcasing antidepressant and cognitive benefits.
The peptide, named DGX-001, shows potential to influence the vagus nerve and help with conditions like dementia. It acts on the AVPR1a receptor found in the gut, which plays a role in mood and stress management. Early studies show that DGX-001 has both cognitive improvements and antidepressant effects. Participants in clinical trials reported better sleep and reduced anxiety.
In their Phase I trials, researchers noted that stimulating the AVPR1a receptor led to significant cognitive benefits. It seems that when this receptor is activated, signals are sent through the vagus nerve to the brain, promoting positive mental health. It was particularly noted that the benefits of DGX-001 were clear; when vagal nerve signals were interrupted in tests, the antidepressant effects vanished.
Current data show increasing excitement around DGX-001. A recent study indicated potential improvement in dementia symptoms in Alzheimer’s and Parkinson’s patients. Improved cognitive scores were seen, along with favorable results from brain activity tests like EEGs. These findings suggest that DGX-001 may be more effective than existing FDA-approved medications for cognitive impairment.
Ohinata believes these results show a broader trend: our diets may play a significant role in our mental health. “Improving the environment around the brain can lead to better brain function,” he stated. Factors like diabetes and high-fat diets can impact cognitive health negatively.
The potential of these diet-derived peptides extends beyond depression and dementia. Researchers at Viage are even exploring their efficacy for serious mental illnesses like schizophrenia. This research aims to leverage everyday foods in creating effective treatments.
Though the initial results of DGX-001 are promising, ongoing clinical trials are necessary. Ohinata hopes that this research can lead to discovering more therapeutic peptides from common foods, providing a safe and accessible way to address mental health challenges.
In short, the gut-brain connection has moved from theory to practical solutions. As researchers continue their work, there’s hope that ordinary foods could yield extraordinary treatments in mental health.
For more information, you can check out the clinical trial on DGX-001.
